Quote Overview

Stock Activity

Open	25.66
Day Low	25.51
Day High	26.40
52 Wk Low	19.37
52 Wk High	47.48
Avg. Volume	1,308,730
Market Cap	2.50 B
Dividend	NA
Beta	1.85

Key Earnings Data

Earnings ESP	2.28%
Most Accurate Est	-1.20
Current Qtr Est	-1.23
Current Yr Est	-5.17
Exp Earnings Date	8/1/24
Prior Year EPS	-5.42
Exp EPS Growth (3-5yr) 29.26%
Forward PE	NA
PEG Ratio	NA

Medical » Medical - Biomedical and Genetics

Research Reports for NTLA

All Zacks’ Analyst Reports

Premium Research for NTLA

Style Scores F Value F Growth A Momentum F VGM
Zacks Rank	Hold 3
Zacks Industry Rank	Top 35%(88 out of 252)
Zacks Sector Rank	Top 31% (5 out of 16)
Earnings ESP	2.28%
Research Reports for NTLA Analyst \| Snapshot

( = Change in last 30 days)

View All Zacks Rank #1 Strong Buys

Premium Research: Industry Analysis

Top Peers	Symbol	Zacks Rank
Intellia Therapeutics	NTLA
Basilea Pharmaceutica	BPMUF
ALX Oncology Holdings	ALXO
AN2 Therapeutics	ANTX
ANI Pharmaceuticals	ANIP
Acumen Pharmaceuticals	ABOS
Adlai Nortye Ltd. Sponsored ADR	ANL

See all Medical - Biomedical and Genetics Peers

Zacks News for NTLA

No Record found.

Company Summary

Cambridge, MA-based Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the therapy and ex vivo programs that use CRISPR to create the therapy by using engineered human cells.

In Vivo Programs: Intellia has multiple in vivo programs. The company is evaluating its leading in vivo genome-editing candidates — NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE). Intellia is planning to file an investigational new drug (IND) application seeking approval to begin clinical studies on NTLA-3001 for alpha-1 antitrypsin deficiency (AATD)-associated lung disease shortly.

Ex Vivo Programs: Intellia is developing multiple preclinical programs that utilize its allogeneic platform for the treatment of immuno-oncology and autoimmune diseases. These programs are being developed as wholly-owned and also in collaboration with partners.

NTLA-2001 is part of a co-development and co-promotion agreement with Regeneron Pharmaceuticals. While Intellia is the lead party for NTLA-2001, Regeneron shares 25% of the development costs and commercial profits. Intellia and Regeneron are also working on developing therapies for hemophilia A and hemophilia B, with Regeneron being the lead party.

Intellia is currently identifying collaboration opportunities to advance the development of NTLA-6001 for CD30+ lymphomas. Also, based on the prioritization of resources, the company has decided to halt further IND-enabling activities for NTLA-2003 to advance an AATD research-stage program.

With no marketed products in its portfolio, Intellia Therapeutics only generates collaboration revenues. In 2023, the company generated $36.3 million of collaboration revenues compared with $52.1 million in 2022.